Urs Ochsner

Crestone, Inc.

$40,390,611

Attributed

$40,390,611

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $14.8M · FY2019–24

$20M$15M$10M$5M$0

'19

'20

'21

'22

'23

'24

Funding mix

By agency

NIH$40,390,611 · 2

By mechanism

N01$40,390,611 · 2

Top collaborators

No co-investigators on record.

Most similar at Crestone, Inc.

Same institution · by research overlap

Thale Cross Jarvis$6,890,861
Jarvis Thale$5,951,244
Urs Oschner$8,499,692
Urs Arnold Ochsner$1,724,814

Others in their field

Other Emerging Leaders on “Advanced Development”

Bambra Strokes · Ppd Development Lp$526,656,217
Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
Chanza Baytop · Westat, Inc.$271,217,917
Valerie Koch · University Corporation For Atmospheric Res$243,972,016
Joel A Lipkin · Four Points Technology, Llc$181,896,915
Kimberly Smith · Ppd Development Lp$115,671,664

Research focus

Advanced DevelopmentPre-ClinicalProduct DevelopmentResearch And DevelopmentTherapeutic CandidateTherapeutic DevelopmentPathway InteractionsBacterial Antibiotic ResistanceEfficacy EvaluationSafety AssessmentGram-Positive BacteriaAntimicrobial ResistanceClostridium DifficileEmerging Communicable DiseasesChemistryCategoriesPhase Ii Clinical TrialsPriority PathogenSafetyNational Institute Of Allergy And Infectious DiseaseManufactureBiodefenseClinical AssessmentsCombating Antibiotic Resistant Bacteria